Indian Hospital Stocks 2026: 4 BUY Picks — Sharekhan Report

Spread love

Apollo, Medanta, Rainbow, and Yatharth offer distinct but complementary growth plays as India’s private healthcare market races toward $364 billion by 2034, says new sector report.

By S. JHA

Mumbai, May 11, 2026 — India’s private hospital sector is at an inflection point, and institutional money is taking notice. Mirae Asset Sharekhan has initiated coverage on four listed hospital chains — Apollo Hospitals, Global Health (Medanta), Rainbow Children’s Medicare, and Yatharth Hospital & Trauma Care Services — all with a BUY rating, in a comprehensive sector report dated May 8, 2026, titled Hospitals: On an Expansion Spree.

The brokerage paints a structurally compelling backdrop: India’s hospital market has surged from $75.3 billion in 2018 to $193.4 billion in FY25, a CAGR of 14.4%, and is projected to reach $364.6 billion by 2034. The private segment is expected to outpace the overall market, compounding at roughly 10.6% annually. The single most persuasive data point underpinning the bull case is India’s chronic bed shortage: at 1.3 beds per 1,000 people, the country sits far below the global median of 2.9, and well behind developing peers such as Brazil (2.5), Malaysia (2.0), and Vietnam (2.6). That structural deficit, Sharekhan argues, means capacity additions will be absorbed without demand drying up for years to come.

Apollo: Scale and Demerger Value

Apollo Hospitals, India’s largest integrated private healthcare network, carries the highest price target in the coverage at Rs 9,418 (CMP: Rs 8,097), implying 16% upside. With 76 hospitals, 10,325 capacity beds, ARPOB exceeding Rs 70,000, and occupancy above 65%, Apollo’s scale is unmatched. An Rs 8,200 crore capex programme targets over 3,500 additional beds by FY28. The anticipated FY27 demerger of its pharmacy and diagnostics arms into separately listed entities is expected to unlock a further 15–20% valuation upside.

Medanta: Greenfield Growth, Clean Balance Sheet

Global Health (Medanta) is the report’s standout long-term compounder. Despite a more modest current scale of approximately 3,000 beds across six hospitals, its Rs 4,000 crore greenfield expansion targets a near-doubling to 6,000 beds in Noida, Mumbai, Guwahati, and Varanasi. What sets Medanta apart is its financial discipline: OCF/Capex has consistently run at 1.5–3x over five years, driving net debt down from 0.7x to 0.2x EBITDA by FY25 — rare for a hospital chain in aggressive growth mode. Price target: Rs 1,494 (24% upside).

Rainbow: Niche Dominance, Best-in-Class Cash Flows

Rainbow Children’s Medicare is India’s only large-scale pure-play pediatric and perinatal hospital chain, and that niche creates significant pricing power. EBITDA margins of 32–34% are the highest in the peer group, and negative working capital days of -110 to -120 eliminate external funding needs entirely. Its hub-and-spoke model limits annual capex to roughly Rs 260 crore. The pivot into Delhi-NCR — historically absent from Rainbow’s map — opens India’s highest-income, highest-fertility corridor. Price target: Rs 1,534 (18% upside).

Yatharth: Fast Growth, Improving Mix

The smallest name in the coverage, Yatharth Hospital has delivered 30% revenue CAGR over FY22–25 and trades at a near-zero debt-equity ratio following post-IPO deleveraging. Its deliberate shift away from government-scheme revenues — targeting a reduction from 35% to 25% — will improve working capital cycles and lift free cash flow conversion. A growing share of complex cardiology, neurology, and oncology cases is driving ARPOB higher at its North India facilities. Price target: Rs 1,015 (18% upside).

The overarching theme of the report is clear: India’s hospital sector has completed its post-COVID deleveraging phase and entered a new capex cycle — this time backed by stronger balance sheets, better payer mixes, and rising insurance penetration, with health insurance premiums growing at a 16% CAGR since FY21. For investors seeking long-duration compounding in domestic consumption, the sector offers a rare combination of structural demand, improving return ratios, and visible earnings growth through FY28.

(This article is for informational purposes only and does not constitute investment advice.)